190 related articles for article (PubMed ID: 21386708)
1. Newer inotropes in pediatric heart failure.
Hoffman TM
J Cardiovasc Pharmacol; 2011 Aug; 58(2):121-5. PubMed ID: 21386708
[TBL] [Abstract][Full Text] [Related]
2. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan: implications for clinicians.
McBride BF; White CM
J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
[TBL] [Abstract][Full Text] [Related]
4. A promising new inotrope: levosimendan.
Fotbolcu H; Duman D
Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
[TBL] [Abstract][Full Text] [Related]
5. Levosimendan: a new option in acute cardiac failure.
Holley AD; Ziegenfuss M
Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
[No Abstract] [Full Text] [Related]
6. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
7. The utility of levosimendan in the treatment of heart failure.
Lehtonen L; Põder P
Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
9. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
Ng TM
Pharmacotherapy; 2004 Oct; 24(10):1366-84. PubMed ID: 15628834
[TBL] [Abstract][Full Text] [Related]
10. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
Kota B; Prasad AS; Economides C; Singh BN
J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
Antoniades C; Antonopoulos AS; Tousoulis D; Bakogiannis C; Stefanadi E; Stefanadis C
Curr Drug Metab; 2009 Feb; 10(2):95-103. PubMed ID: 19275545
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
14. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
[TBL] [Abstract][Full Text] [Related]
15. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
Cavana M; Pignataro C; Fraticelli A; Mebazaa A
Ital Heart J; 2003 May; 4 Suppl 2():61S-64S. PubMed ID: 14635372
[TBL] [Abstract][Full Text] [Related]
16. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
[TBL] [Abstract][Full Text] [Related]
17. [Levosimendan. Clinical indications of a new vasoactive substance].
Braun JP; Döpfmer U; Kastrup M; Roots I; Borges A; Schneider M; Dohmen P; Kox W; Spies C
Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
[TBL] [Abstract][Full Text] [Related]
18. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
Erhardt LR
Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan: dual mechanisms for acute heart failure...and beyond?
Ng TM; Akhter MW
Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
[TBL] [Abstract][Full Text] [Related]
20. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Wehrens XH
Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
